Novel tumor calibrated inhibitor, showing unique polypharmacology and strongly improved therapeutic index in fly and human MTC xenograft models

Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing

Aminoglycoside antibiotic used in veterinary medicine

Novel anticancer agent, arresting MCF-7 cell growth at G2/M phase and S phase, dose dependent increasing in the mitochondrial membrane potential (ΔΨm) and ROS levels, decreasing in Gal-1 protein levels

Novel inducer of cell death by activating apoptosis in cancer cells

Inhibitor of HMG-CoA-reductase, promoting apoptosis of myeloma cells in vitro

Potent inhibitor of Bcl-2 and Mcl-1, acting as a BH3 mimetic

Novel apolipoprotein E4 (apoE4) stabilizer, showing activity in an IL-6 and IL-8 cytokine release assay

Novel inducer of endogenous ApoA-I, protecting against atherosclerotic lesion development in ApoE-/- mice, upregulating the apolipoprotein A-I gene expression, enhancing its function of promoting cholesterol efflux, ABCA1 expression and activation of PPAR

Novel extremely potent inhibitor of APN activity in vitro, selective against other zinc-dependent enzymes such as matrix metalloproteases, and possessed limited cytotoxicity against Ad293 cells and favorable physicochemical and metabolic stability propert

Potent aminopeptidase N/CD13 (APN) inhibitor

Histamine H3 receptor antagonist

Novel inhibitor of PCAF bromodomain/Tat-AcK50 association

Selective A2a adenosine receptor agonist

Novel inhibitor of PCAF bromodomain/Tat-AcK50 association

Novel inhibitor of the Ap4A phosphorylase (Rv2613c) of Mycobacterium tuberculosis (Mtb)

Potent and selective antitumor agent, effectively depleting cellular Fe, resulting in transferrin receptor-1 up-regulation, ferritin down-regulation, and increased expression of the potent metastasis suppressor, N-myc downstream regulated gene-1

Novel inhibitor of the gatekeeper mutant of BCR-ABL, suppressing in vitro resistance

Novel highly potent and selective Src_%28gene%29>Src kinase inhibitor

Inhibitor of both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation

Novel highly potent and selective α4β2 nAChR antagonist

Cyclooxygenase inhibitior

Novel tumor-targeting cytotoxic agent

Novel anticancer agent, targeting PPARγ and HDAC4, being cytotoxic to CCRF-CEM cells (CC50 = 2.8 μM), inducing apoptosis, and causing DNA fragmentation, modulating the expression of c-Myc, cleaving caspase-3, and causing in vivo tumor regression in CCRF-C

Novel cellular anticancer agent, exhibiting 7.9-341.7-fold antiproliferative activities against four cell lines, Aspc-1 (human colon adenocarcinoma cells), H358 (human nonsmall cell lung cancer cells), HCT116 (human colorectal adenocarcinoma cells), and S

Novel antitubercular agent, exerting growth inhibition of Mtb during parasitism of host macrophages

Novel anti-SARS-CoV-2 agent, displaying in vitro antiviral activity with IC 50 0.016 µM and Mpro inhibition activity with IC 50 0.013 µM, showing potent activity against human TMPRSS2 and furin enzymes with IC 50 0.05, and 0.08 µM, respectively

Novel antioxidant, binding copper in a unique manner compared to other chelates proposed to treat Alzheimer's disease and protecting HT-22 neuronal cells from cell death induced by Aβ + copper(II)

Novel anti-MERS-CoV agent against virus-infected Huh7 cells

Novel idebenone analog, demonstrating significantly higher potency ex vivo, and significantly lower cytotoxicity, than idebenone in the treatment of Leber's Hereditary Optic Neuropathy (LHON)